HCW Biologics Inc. (HCWB) stock
HCWBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/3095% below fair value
$0.76−0.01 (-1.65%)
Close on Nov 18, 2026Market cap $1.40MP/E –Yield –
HCW Biologics gross margin
Gross margin is gross profit as a percentage of revenue.
HCW Biologics's gross margin for the twelve months ending Jun 30, 2026 was 96.7%. For fiscal 2025 it was 20.0%, against 37.4% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 20.0% | −17.4 |
| FY2024 | Dec 31, 2024 | 37.4% | +17.7 |
| FY2023 | Dec 31, 2023 | 19.7% | −18.8 |
| FY2022 | Dec 31, 2022 | 38.5% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -77.1% | −97.1 |
| Q1 FY2026 | Mar 31, 2026 | 100.5% | +80.5 |
| Q4 FY2025 | Dec 31, 2025 | 20.0% | −0.0 |
| Q3 FY2025 | Sep 30, 2025 | 20.0% | −0.0 |
| Q2 FY2025 | Jun 30, 2025 | 20.0% | −9.2 |
| Q1 FY2025 | Mar 31, 2025 | 20.0% | −34.6 |
| Q4 FY2024 | Dec 31, 2024 | 20.0% | +0.9 |
| Q3 FY2024 | Sep 30, 2024 | 20.0% | −0.5 |
| Q2 FY2024 | Jun 30, 2024 | 29.2% | +9.8 |
| Q1 FY2024 | Mar 31, 2024 | 54.6% | +24.6 |
| Q4 FY2023 | Dec 31, 2023 | 19.1% | −0.9 |
| Q3 FY2023 | Sep 30, 2023 | 20.5% | +0.5 |
| Q2 FY2023 | Jun 30, 2023 | 19.3% | −17.4 |
| Q1 FY2023 | Mar 31, 2023 | 29.9% | −27.5 |
| Q4 FY2022 | Dec 31, 2022 | 20.0% | – |
| Q3 FY2022 | Sep 30, 2022 | 20.0% | – |
| Q2 FY2022 | Jun 30, 2022 | 36.7% | – |
| Q1 FY2022 | Mar 31, 2022 | 57.4% | – |
See a number that looks wrong?